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Abstract
Psychiatric diseases, including schizophrenia, bipolar disorder and major depression, are projected to lead global disease
burden within the next decade. Pharmacotherapy, the primary – albeit often ineffective – treatment method, has remained
largely unchanged over the past 50 years, highlighting the need for novel target discovery and improved mechanism-based
treatments. Here, we examined in wild type mice the impact of chronic, systemic treatment with Compound 60 (Cpd-60), a
slow-binding, benzamide-based inhibitor of the class I histone deacetylase (HDAC) family members, HDAC1 and HDAC2, in
mood-related behavioral assays responsive to clinically effective drugs. Cpd-60 treatment for one week was associated with
attenuated locomotor activity following acute amphetamine challenge. Further, treated mice demonstrated decreased
immobility in the forced swim test. These changes are consistent with established effects of clinical mood stabilizers and
antidepressants, respectively. Whole-genome expression profiling of specific brain regions (prefrontal cortex, nucleus
accumbens, hippocampus) from mice treated with Cpd-60 identified gene expression changes, including a small subset of
transcripts that significantly overlapped those previously reported in lithium-treated mice. HDAC inhibition in brain was
confirmed by increased histone acetylation both globally and, using chromatin immunoprecipitation, at the promoter
regions of upregulated transcripts, a finding consistent with in vivo engagement of HDAC targets. In contrast, treatment
with suberoylanilide hydroxamic acid (SAHA), a non-selective fast-binding, hydroxamic acid HDAC 1/2/3/6 inhibitor, was
sufficient to increase histone acetylation in brain, but did not alter mood-related behaviors and had dissimilar transcriptional
regulatory effects compared to Cpd-60. These results provide evidence that selective inhibition of HDAC1 and HDAC2 in
brain may provide an epigenetic-based target for developing improved treatments for mood disorders and other brain
disorders with altered chromatin-mediated neuroplasticity.
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Introduction
Epigenetic mechanisms involving chromatin-modifying en-
zymes and remodeling factors are increasingly implicated in the
pathophysiology of mood (affective) disorders including depression
and bipolar disorder, as well as in other psychiatric diseases such as
schizophrenia [1]. Neuroplasticity – the capacity for changes in
brain function – is relevant to understanding both disease states
and effective treatment mechanisms. These changes involve
dynamic modulation of chromatin– DNA packaged around
octameric cores of histone proteins H2A, H2B, H3 and H4 -
which is subject to diverse post-translational modifications.
Acetylation of histone amino-terminal tails is associated with an
open chromatin structure that facilitates the binding of transcrip-
tional activating protein complexes that modulate gene expression
[2] and alter neural circuit function. Histone deacetylase (HDAC)
enzymes, including subtypes comprising class I (HDAC1, 2, 3 and
8) and class II (HDAC 4–7, 9 and 10), control the deacetylation of
histone and non-histone proteins. These enzymes are therefore
important mediators in epigenetic regulation of gene expression
that may contribute to mechanisms underlying psychopathology
and treatment.
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e71323
Recent findings indicate that the activity of specific class I and II
HDAC enzymes may be altered in psychiatric disease and may
play a role in effective clinical treatments.
Postmortem studies have revealed altered mRNA and protein
expression of HDAC1, 2 and 5 among patients with major
depressive disorder, schizophrenia and bipolar disorder [3–5].
Valproate, a drug widely used in bipolar disorder treatment,
functions in part as an inhibitor of all class I HDACs [6,7].
Moreover, lithium therapy, a mainstay bipolar disorder treatment
and antidepressant adjunct, as well as the typical antipsychotic,
haloperidol, were shown to increase histone acetylation in cellular
and animal models [8–11]. Further, HDAC2 was recently
demonstrated to be a key regulator of atypical antipsychotic
response [12]. Thus, investigating altered histone acetylation in the
context of mood and psychotic disorders may provide insight
toward critical factors regulating plasticity as well as novel
therapeutic targets based on epigenetic mechanisms.
Animal model research further supports the link between
HDAC activity and mood disorders. Electroconvulsive therapy,
used in treatment-resistant depression, was shown to alter histone
H3 and H4 acetylation at the promoter regions of actively
transcribed genes in rat hippocampus [13]. Additional rodent
behavioral data demonstrate antidepressant-like effects of the class
I HDAC inhibitor, sodium butyrate [14], the HDAC1/2/3
inhibitor, MS-275 [3], as well as reduced psychostimulant-induced
hyperactivity by valproate and sodium butyrate [15,16]. However,
these reports used weak inhibitors with low selectivity for different
class I HDAC subtypes that may engage non-HDAC targets at
high physiological concentrations (millimolar range). Thus, the
class I HDAC subtypes critical to the observed effects remain
unclear.
To further investigate the mechanism of HDAC inhibition in
the underpinnings and treatment of mood disorders, we identified
from the literature Cpd-60 (Compound 19, also published as
Compound 60), a benzamide-based, subclass selective inhibitor of
HDAC1 and HDAC2 [17,18]. Cpd-60 has structural features
distinct from previously studied compounds that make it an
excellent probe compound. We demonstrate here, for the first
time, that chronic treatment of mice with Cpd-60 results in
substantial effects in two behavioral tests with predictive validity
for mood stabilizer and antidepressant medications. Cpd-60
treatment was associated with significant gene expression changes
in prefrontal cortex (PFC), nucleus accumbens (NAc) and
hippocampus (HIP), brain regions involved in the regulation of
mood [19,20], through an HDAC inhibition-mediated mechanism
evidenced by increased histone acetylation at gene promoter
regions. Interestingly, a small subset of gene expression changes
induced by Cpd-60 significantly overlap with those induced by
lithium, suggesting common mechanistic elements that may play a
role in altering behavior. Together, this study demonstrates that
selective inhibition of HDAC1 and HDAC2 in mice modulates
transcription in mood circuits and alters relevant behaviors, and
may be a viable mechanism for the development of clinical mood
disorder treatments.
Materials and Methods
Chemical Synthesis
Cpd-60 and SAHA were synthesized according to published
protocols [18,21,22]. All compounds were greater than 95% purity
and stored at 220uC as dry powders prior to use.
Animals
Male 11 wk old C57BL/6 mice were utilized for pharmacoki-
netic, behavioral and biochemical analyses. One female baboon
(Papio Anubis) was used to determine brain uptake and pharma-
cokinetics of Cpd-60. Ethics Statement: All animal work was
approved conduced under strict accordance to the ethical
standards set by the Massachusetts Institute of Technology
Institutional Animal Care and Use Committee (IACUC) and the
Committee on Animal Care (mouse experiments, internal protocol
#0410-03-013) and by the Brookhaven National Laboratory
IACUC (baboon experiment, protocol #102). Non-human
primate housing conditions and feeding regimens were coordinat-
ed by the professional investigative staff at the Brookhaven
Laboratory Animal Facility which included social housing in cages
appropriate for the physical and behavioral health of the
individual animal. Animals were fed a 3x per day with additional
nutritional supplements provided as prescribed by the attending
veterinarian. Environmental enrichment included audio, video
and tactile elements (e.g. listening to the radio, watching television,
playing with toys and human interaction) and were provided on a
daily basis to promote psychological well-being. All procedures
were performed without compromising animal welfare and all
efforts were made to minimize suffering including adequate use of
anesthesia (ketamine, isoflurane) in the baboon imaging experi-
ment. The baboon was not sacrificed following the study and
further effort was taken to minimize suffering by allowing an
interval of at least one month between subsequent imaging studies
in the same animal.
Pharmacokinetic Profile Determination
Mice were treated (i.p.) with Cpd-60 (45 mg/kg) or SAHA
(25 mg/kg) in vehicle (10% DMSO, 45% PEG400, 45% saline)
and blood collected by retro-orbital puncture into heparinized
tubes at pre-treatment, and 0.083, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hr
post-treatment (n = 3 mice/group), followed by immediate sacrifice
and brain harvest. Plasma, brain samples, and dose formulations,
were analyzed as previously described [23] using high perfor-
mance liquid chromatography/mass spectrometry. Data acquisi-
tion and control system were created using Analyst 1.4 software
(ABI Inc, Canada).
CNS Target Binding Assays
Cpd-60 was submitted to a panel of 80 binding assays for
common transmembrane and soluble receptors, ion channels and
monoamine transporters in the central nervous system (CNS)
(High-Throughput Profile P-3, Cerep, France). Cpd-60 (10 mM)
was assayed in duplicate concurrently with an assay-specific
reference compound (Table S1).
Biochemical Assays
HDAC activity was measured in vitro using recombinant human
HDACs 1-9 (BPS Bioscience) using the Caliper EZ reader II
system. HDAC inhibition assays: Purified HDACs were incubated
with a FAM-labeled fluorescent substrate and test compound at
room temperature for 60 min or, for HDAC 1-3, 180 min to
control for effects of slow-binding inhibitors on HDAC activity.
Fluorescence intensity of electrophoretically separated substrate
and product was measured and the percent inhibition plotted
against compound concentration. IC50 values were determined by
curve fitting with Origin 8.0 software [24]. Binding kinetics: Binding
kinetics of Cpd-60 and SAHA with HDACs 1, 2, and 3 were
evaluated by progression curves in inhibition and dilution
experiments as previously described [25].
Mood-Related Effects of HDAC1/2 Inhibition in Mice
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Mouse Primary Neuronal Histone Acetylation Assays
Mouse primary neurons cultured 13 days in vitro were treated
with HDAC inhibitors for 24 hr, fixed with 4% formaldehyde, and
stained with an anti-acetylated H4 lysine 12 antibody and an
Alexa-488 conjugated secondary antibody, with nuclei identified
using a Hoechst stain. Cells with histone acetylation signals above
an intensity threshold of .99.5% were scored as ‘‘bright green
cells’’ and expressed as a percentage normalized to DMSO
controls. EC50 values were determined from curve fitting using
GraphPad Prism v5 software (GraphPad Software, Inc., USA).
Pharmacological Treatments
Cpd-60 (45 mg/kg, 7.5 mL/kg, i.p.) and SAHA (25 mg/kg,
5 mL/kg, i.p.) were prepared fresh for daily injection in vehicle
(10% DMSO, 45% PEG-400, 45% saline). D-amphetamine
(Sigma-Aldrich) was prepared in saline and administered via i.p.
injection (3.5 mg/kg, 5 mL/kg).
Behavioral Procedures
Compounds were administered between 9 am and 1 pm for 7
days prior to the start of behavioral testing, and after completion of
each daily session during behavioral testing. Testing was
performed 18–24 hr after the previous treatment to avoid
transient effects. Amphetamine-induced hyperlocomotion (AIH)
was performed as previously described [26] on days 7–9 of
treatment with activity measured before and after amphetamine
challenge (AccuScan Instruments, Inc.). Forced-swim test (FST)
behavior was performed as previously described [26] on day 10 of
treatment and total time spent immobile during a 6 min session
was scored automatically (Ethovision; Noldus). Treatment effects
were analyzed by one way analysis of variance (ANOVA) with post
hoc analysis using Least Squared Differences test (SPSS v18.0
IBM).
Brain Tissue Collection
Behaviorally naı¨ve mice were treated daily (i.p.) with Cpd-60
(45 mg/kg), SAHA (25 mg/kg) or vehicle. One hour after the last
of 10 treatments, harvested brains were snap frozen and stored at
280uC until use. Independent sets of treated brains were used for
western blotting, transcriptional analysis, and chromatin immu-
noprecipitation, as detailed below.
Western Blotting
Frozen mouse brains (n= 6/treatment group) were rapidly
dissected at 4uC to isolate frontal cortex (including PFC), ventral
striatum (including NAc), and HIP for protein extraction. Human
Embryonic Kidney (HEK) 293 cells were treated with 20 mM
Cpd-60, SAHA or DMSO for 24 hr ‘constant’ treatment, followed
by media change and 6 hr incubation (‘washout’), and cells
collected for protein extraction. Solutions for protein extraction
were supplemented with 5 mM sodium butyrate to suppress
residual HDAC activity. Western blotting was performed using
standard protocols and commercially available antibodies (Milli-
pore) raised against acetylated histone H2B (07-373), H3K9 (07-
352), and H4K12 (04-119) with normalization to total levels of
histone H3 (07-690) or histone H4 (04-858). Densitometric
quantification was performed using Image J software (NIH) and
statistical comparison to vehicle-treated controls by two-tailed t-
test.
RNA Isolation and Transcriptional Analysis
Frozen mouse brains (n= 6/treatment group) were rapidly
dissected at 4uC to isolate medial prefrontal cortex (PFC), nucleus
accumbens (NAc) and hippocampus (HIP) for mRNA extraction.
Whole genome transcript profiling was performed using the
Illumina MouseWG-6 Expression BeadChip with subsequent
validation by quantitative real-time PCR (qPCR) and is available
online at the NCBI Gene Expression Omnibus repository
(GSE47452).
Chromatin Immunoprecipitation
Native chromatin immunoprecipitation (ChIP) was performed
as previously described with minor modifications [27]. Frozen
mouse brains treated with Cpd-60 or vehicle (n = 4/group) were
rapidly dissected at 4uC and NAc isolated. Nucleosomal chromatin
(‘Input’) was prepared by digesting native (unfixed) chromatin with
micrococcal nuclease. 100 mL of the ChIP product was incubated
overnight with anti-histone H4K12ac antibody and precipitated
using agarose beads (Santa Cruz #SC-2003). Purified, immuno-
precipitated DNA was applied to qPCR using primers (Table S2)
designed using NCBI PRIMER-BLAST targeting regions proxi-
mal to gene transcription start sites (TSS). Resulting DNA
amplification curves were used to calculate the ratio of immuno-
precipitated DNA from ChIP to Input with statistical significance
determined by two-tailed t-test of Cpd-60 or SAHA compared to
vehicle.
Results
Characterization of Cpd-60 as a Brain-penetrant, Selective
Inhibitor of HDAC1 and HDAC2
In order to assess the utility of Cpd-60 (Fig. 1a) for in vivo studies,
we initially determined its target selectivity and potency, binding
kinetics, activity in cultured mouse neurons and brain penetrance.
For comparison, we also assessed these parameters for SAHA
(Fig. 1a), a non-selective inhibitor of class I and class II HDAC
subtypes that has been demonstrated in mice to enhance cognition
following chronic systemic treatment [28] and improve depres-
sion-related behaviors when directly infused into brain [3].
Using a fluorometric biochemical assay (Fig. 1b.), we confirmed
the selective inhibition by Cpd-60 of HDAC1 and HDAC2
(IC50 = 1 and 8 nM) with 50–400 fold selectivity over class I
HDAC3 (IC50 = 458 nM), and no appreciable inhibition of
HDAC8 or of the class II HDACs (IC50.30 mM). Additional
biochemical assays revealed high-affinity (Ki = 0.2–1.5 nM) and
slow-on/slow-off binding kinetics of Cpd-60 to HDAC1 and
HDAC2 with half-lives (T1/2) of 40- and 80-hr (2400–4800 min;
Fig 1c). Cpd-60 had lower affinity (Ki = 270 nM) and engagement
of HDAC3 (T1/2 = 20 hr Fig.1c). In comparison, SAHA exhibited
potent inhibition of HDAC1, 2, 3 and 6 (IC50 = 2–11 nM; Fig. 1b),
similar to previously published results [6], and fast-on/fast-off
binding kinetics (T1/2,4 min for HDAC1–3; Fig. 1c).
A subsequent counter screen against 80 common CNS targets
including receptors, channels and transporters (Table S1),
identified a clean profile for Cpd-60 (10 mM), with no significant
binding to any of the targets (50% inhibition of control binding).
These data suggest that biological effects of Cpd-60 are likely due
to its inhibitor activity towards HDAC1 and HDAC2, and are not
due to off-target effects.
To determine whether the binding kinetics of Cpd-60 and
SAHA correlated with changes in cellular HDAC activity over
time, we examined the acetylation of histone H4 at lysine 12
(H4K12ac) by western blot in HEK293 cells exposed to Cpd-60 or
SAHA. Treatment with either inhibitor (20 mM for 24 hr) elevated
H4K12ac levels (Fig. 1d, ‘constant’), however 6 hr after media
change (Fig. 1d, ‘washout’), only Cpd-60-treated cells showed
persistent increases in H4K12ac, indicating lasting HDAC binding
Mood-Related Effects of HDAC1/2 Inhibition in Mice
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and functional inhibition. To verify neuronal HDAC inhibitory
activity of Cpd-60 and SAHA, we measured histone acetylation in
cultured primary mouse forebrain neurons using an immunoflu-
orescence-based, laser-scanning cytometry assay. Treatment with
Cpd-60 or SAHA (20 mM) for 24 hr induced dose-dependent
acetylation of H4K12ac (Fig. 1e) with EC50 values of 7.2 mM and
0.6 mM for Cpd-60 and SAHA, respectively, demonstrating robust
inhibition of HDACs in cultured neurons.
Brain pharmacokinetic analyses (Fig. 1f) using doses corre-
sponding to subsequent behavior and transcript expression
studies determined that Cpd-60 had sustained brain exposure
(T1/2 = 6.44 hr) compared to SAHA (T1/2 = 0.44 hr). The
maximum concentration (Cmax) of Cpd-60 was 0.83 mM, far
exceeding the in vitro IC50 for HDAC1 and HDAC2 (0.001 and
0.008 mM) but not HDAC3 (0.4 mM), suggesting robust
inhibition of HDAC1 and 2. Preliminary positron emission
tomography data following intravenous treatment of carbon-11
labeled Cpd-60 in baboon, collected as previously described
[29], were consistent with rodent data and confirmed that Cpd-
60 reaches the brain, albeit at low levels relative to plasma
(S.W.K., J.M.H. unpublished data).
Figure 1. In vitro and in vivo characterization of two structural classes of HDAC inhibitors. (a) Chemical structure of SAHA and Cpd-60. (b)
In vitro IC50 (mM) for HDAC 1-9 by SAHA and Cpd-60 using recombinant human HDAC enzymes and HDAC class-specific substrates. Inhibitor and
substrate were incubated for 60 min (HDAC4-9) or 180 min (HDAC1-3)a to control for HDAC1-3 inhibition by slow-binding test compounds. (c) In vitro
binding affinity (Ki) and kinetics (half-life ‘T1/29 in minutes) for HDAC 1, 2 and 3 incubated with SAHA or Cpd-60 (10 mM). (d) H4K12 acetylation levels in
HEK293 cells following 24 hr ‘constant’ exposure to DMSO, SAHA (20 mM) or Cpd-60 (20 mM) and 6 hr after drug ‘washout’ (media change) with
tubulin loading control. (e) Dose response plots for induction of histone H4K12 acetylation in cultured primary mouse neuronal cells by SAHA or Cpd-
60 for 24 hr. Cells with histone acetylation signals above an intensity threshold of .99.5% (‘‘bright green cells’’) are plotted as a percentage
normalized to DMSO control. EC50 values for H4K12 acetylation were 0.60 mM and 72 mM for SAHA and Cpd-60, respectively. (f) In vivo mouse brain
pharmacokinetics following acute systemic administration of SAHA (25 mg/kg, i.p.) or Cpd-60 (45 mg/kg, i.p.).
doi:10.1371/journal.pone.0071323.g001
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Overall, Cpd-60 was confirmed to be brain penetrant with
selectivity and slow-on/slow-off binding for HDAC1/2. These
selectivity and kinetic properties differentiate it from HDAC
inhibitors utilized in prior rodent behavioral studies, including
other benzamides such as the HDAC1/2/3 inhibitor, MS-275, as
well as SAHA [3,19,28].
Validation of Cpd-60 as a Histone Deacetylase Inhibitor in
Mouse Brain
Mood disorder medications, including antidepressants and
lithium, typically require prolonged treatment to be effective in
patients [30]. We emulated this for in vivo experiments using a
chronic drug treatment paradigm (.7 days i.p. treatment). To
confirm that chronic Cpd-60 and SAHA suppressed HDAC
activity in mouse brain, we examined global histone acetylation in
cortex, ventral striatum (including NAc) and Hip, regions
implicated in regulation of mood-related behaviors [19,20].
Histone acetylation was measured one hour after chronic
treatment, a time point at which both Cpd-60 and SAHA are
present in the brain (Fig. 1f). Three histone marks were measured,
H2B (‘tetra’acetyl-K5,12,15, and 20), H3K9ac, and H4K12ac,
which are associated with active transcription and are sensitive to
HDAC2 activity [28,31]. Consistent with their in vitro activity as
potent HDAC inhibitors, both Cpd-60 and SAHA significantly
increased acetylation in each brain region by 1.5- to 2.0-fold
compared to vehicle, indicating both compounds suppress HDAC
activity in the brain following systemic administration (Fig. 2). The
magnitude of change was consistent with previous studies of mouse
brain [3,6,14] and suggest that, despite differences in binding
kinetics, HDAC subtype selectivity, and pharmacokinetic profiles,
chronic treatment with Cpd-60 or SAHA induce similar increases
in global histone acetylation in brain regions relevant to mood.
Chronic Treatment with Cpd-60 Improves Mood-related
Behaviors in Mice
We next examined the efficacy of Cpd-60 in two established
mouse behavioral assays with predictive validity for mood-
stabilizer and antidepressant medications; the amphetamine
induced hyperlocomotion (AIH) assay and the forced swim test
(FST) assay. The AIH assay, in which amphetamine challenge
significantly increases locomotor activity, has predictive validity for
mood-stabilizing drugs, including lithium and valproate, which
significantly attenuate the increased locomotion [16,26,32].
Published work from our group has confirmed the attenuating
effects of lithium treatment on hyperlocomotion in wild type mice
[26]. Following chronic treatment, Cpd-60 (45 mg/kg, i.p.)
significantly reduced hyperlocomotion by 36% (Ftreatment
(2,33) = 3.581, post hoc p,0.05), whereas SAHA (25 mg/kg, i.p.)
had no effect (p = 0.54) compared to vehicle-treated mice (Fig. 3a
and b). The attenuating effect of Cpd-60 on hyperlocomotion was
not due to non-specific motoric effects, as basal locomotor activity
was unchanged preceeding amphetamine challenge (Fig. 3a, t220
to 0 min) and during test chamber acclimation on the previous day
(see Methods; average distance traveled +/2 SEM: Cpd-60:
2099 cm +/2249; Vehicle: 1929 cm +/2219). The FST assay is
widely-used for evaluating the efficacy of antidepressants, which
reduce the time spent immobile in a cylinder of water [33,34].
Cpd-60 treatment resulted in a significant 67% reduction in
immobility time compared to vehicle- or SAHA (Fig. 3C, Ftreatment
(2,33) = 6.588, post hoc p,0.01). This indicates an antidepressant-
like effect comparable to that previously observed by our group
after treatment with lithium (85 mg/kg i.p., 48% reduction, [26])
or the tricyclic antidepressant desipramine (15 mg/kg i.p., 55%
reduction, n= 16/group; data not shown). These results suggest
that prolonged inhibition of HDAC1/2 modulates the activity of
mood-related neurocircuitry in mice.
Chronic Cpd-60 Treatment Alters Gene Expression in
Brain Circuits Involved in Mood Regulation
Having observed robust behavioral effects following selective
HDAC inhibition by Cpd-60, we next sought mechanistic insight
into how Cpd-60 modulates molecular pathways regulating mood-
related neurocircuitry. As changes in histone acetylation are linked
to transcriptional regulation, we examined the effect of chronic
HDAC inhibitor treatment on gene expression using whole-
genome expression microarrays. PFC, NAc and HIP were profiled
one hour after the tenth daily treatment of Cpd-60 or SAHA to
investigate transcriptional changes potentially mediated by
increased histone acetylation observed at this behaviorally relevant
time point (Fig. 2). One-way ANOVA tests revealed that treatment
with Cpd-60 or SAHA altered the expression of 4365 transcripts
(uncorrected p,0.05). None of the transcripts survived Benjamini-
Hochberg false discovery rate (FDR) correction at q ,0.05 [35],
however the microarray results were subsequently verified via
quantitative PCR on a subset of genes as detailed below. Post hoc
testing revealed that, summed across the three brain regions, a
similar total number of transcripts were significantly altered by
Cpd-60 or SAHA treatment compared to vehicle (Tukey’s HSD
p,0.05, 1609 transcripts up- or down-regulated by Cpd-60 versus
1530 by SAHA). These changes reflect a regulatory influence of
HDAC inhibitor treatment on only a fraction of the genome (less
than 2000 of the .45,000 transcripts assayed by microarray),
consistent with previous reports [3,31].
Focusing on the subset of genes that were altered at least 1.2-
fold by Cpd-60 or SAHA compared to vehicle (post hoc p,0.05),
dramatic expression differences were detected across brain regions
and inhibitors. Heatmaps illustrating transcripts upregulated or
downregulated by HDAC inhibitor treatment in PFC, NAc or
HIP revealed that Cpd-60 and SAHA altered unique sets of genes,
indicated by distinct heatmap shading for each inhibitor (Fig. 4a).
Large changes in gene expression, shown as intense red/blue
shading, were seldom aligned between Cpd-60 and SAHA,
illustrating little overlap in transcript regulation. Venn diagrams
(Fig. 4b) enumerate transcripts significantly altered by Cpd-60 or
SAHA compared to vehicle ($1.2-fold, post hoc p,0.05) and
highlight striking differences within each of the three brain regions.
Specifically, Cpd-60 treatment altered a similar number of
transcripts in each region (44–70 upregulated, 42–87 downregu-
lated), whereas transcripts altered by SAHA were predominantly
in the HIP (104 upregulated, 148 downregulated), with far fewer
changes detected in the PFC or NAc (7 and 5 upregulated, 5 and
16 downregulated, respectively). Moreover, fewer than ten
transcripts were altered by both Cpd-60 and SAHA in any brain
region, indicating compound-specific effects on gene expression.
To validate our microarray findings, we applied quantitative
real-time PCR (qPCR) to a set of eight genes robustly altered by
Cpd-60 versus vehicle ($1.2-fold, post hoc p,0.05). The qPCR
results (Fig. 4c) were in agreement with the microarray results for
eight of eight genes and provide increased confidence in the
microarray gene expression changes. Specifically, the qPCR
results supported the microarray results by confirming that Cpd-
60 induced robust changes in gene expression, with lesser changes
by SAHA, including increases (e.g. Agxt2l1, Sgk1 and Tsc22d3) and
decreases (e.g. Qdpr, Rock2), as well as validation of null effects (e.g.
Mfsd2 in NAc, Sult1a1 in HIP, Fig.4c; Table S3).
Mood-Related Effects of HDAC1/2 Inhibition in Mice
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Cpd-60 Treatment Increases Histone Acetylation at
Active Gene Promoter Regions
We next sought a mechanistic link between the observed
increases in histone acetylation and changes in gene expression
detected following Cpd-60 treatment. As illustrated by the
schematic in Figure 5a, chromatin immunoprecipitation (ChIP)
and qPCR were used to examine the histone acetylation status of
chromatin surrounding the transcription start site (TSS) of four
genes with the greatest microarray expression changes induced by
Cpd-60 treatment, alanine-glyoxylate aminotransferase 2-like 1
Figure 2. Effects of HDAC inhibitors on histone acetylation in mouse brain. Chronic SAHA (25 mg/kg, i.p.) or Cpd-60 (45 mg/kg, i.p.)
significantly increased acetylation of histone H2B(tetra-acetylated), H3K9 and H4K12 in cortex, ventral striatum and hippocampus one hour after the
10th daily treatment (arbitrary units, relative to vehicle control). Representative western blots are shown with total levels of histone H3 (H3pan) and
histone H4 (H4pan) used as loading controls. *p,0.05, t-test of Cpd-60 or SAHA versus vehicle. n= 6 mice/group.
doi:10.1371/journal.pone.0071323.g002
Figure 3. Effect of Cpd-60 treatment on mood-related behaviors in mice. (a) Timecourse of locomotor activity in response to and (b) total
locomotor activity summed over 80 min following acute amphetamine challenge (3.5 mg/kg, i.p.; Time ‘0’ indicated by arrow). Hyperlocomotion in
response to amphetamine was significantly reduced in mice chronically treated with Cpd-60 (45 mg/kg, i.p.) but not with SAHA (25 mg/kg, i.p.). (c)
Time spent immobile in the forced swim test was significantly decreased in mice treated chronically with Cpd-60 but not SAHA compared to vehicle
treated control mice. *p,0.05, **p,0.01, ANOVA with Least Significant Difference post hoc test.
doi:10.1371/journal.pone.0071323.g003
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(Agxt2l1), serum/glucocorticoid regulated kinase 1 (Sgk1), sulfo-
transferase family 1A phenol-preferring member 1 (Sult1a1), and
TSC22 domain family member 3 (Tsc22d3). We focused on
changes in the NAc as this region integrates dopaminergic and
serotonergic neurotransmission – systems that are central to mood
regulation [36,37]. Additionally, a previous study showed that in
mice, histone acetylation increases in the NAc correlated with
antidepressant-like effects of the HDAC1/2/3 inhibitor MS-275
[3]. We found that H4K12ac was significantly enriched by 2- to
10-fold in Cpd-60-treated mice at regions 0.2 and 1 kb upstream
of the TSS of all four genes (Fig. 5b). In contrast, H4K12ac levels
were lower than vehicle-treated controls in a region 0.5 kB
downstream of each TSS (Fig 5b), indicating that enrichment of
H4K12ac at upstream gene promoters was not due to global, non-
specific increases in histone acetylation. These data suggest that
transcription induced by Cpd-60 results, at least in part, from
increased H4K12 acetylation at gene promoter regions.
Cpd-60 and Lithium Induce Similar Transcriptional Effects
in Brain
The behavioral changes observed in the AIH and FST assays
following chronic Cpd-60 treatment are similar to those that we
Figure 4. Gene expression changes in mouse brain following chronic HDAC inhibitor treatment. (a) Heatmaps illustrating transcript
expression changes in mouse brain following chronic HDAC inhibitor treatment for 10 days. Cpd-60 (45 mg/kg, i.p.) significantly upregulated (red) or
downregulated (blue) a similar number of transcripts in prefrontal cortex (PFC), nucleus accumbens (NAc), and hippocampus (HIP). Expression
changes following SAHA treatment (25 mg/kg, i.p.) were predominantly localized to HIP. (b) Venn diagrams illustrate that only 1–10 genes were
similarly regulated by Cpd-60 and SAHA treatment depending on brain region. Genes included in heatmaps and Venn diagrams have $1.2-fold
expression change compared to vehicle (ANOVA p,0.05 with Tukey’s HSD post hoc test). (c) qPCR validation of a subset of genes with significantly
altered expression following Cpd-60 treatment as determined by microarray analysis. *p,0.05, t-test of Cpd-60 or SAHA compared to vehicle.
doi:10.1371/journal.pone.0071323.g004
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and others have found following treatment with lithium [26,32], as
well as valproate in the case of the AIH assay [15]. Lithium and
valproate are reported to have synergistic effects on histone
acetylation and other molecular targets in mouse models of
neurological disease [8,9], implicating a common mechanism of
the two drugs. We therefore reasoned that Cpd-60 and lithium
treatments may induce similar effects on the transcriptome. A
previous study by McQuillin and colleagues reported that chronic
dietary lithium resulted in significant transcriptional changes (up-
and down-regulation) of 121 transcripts in mouse brain compared
to mice fed a control diet [38]. We therefore used Gene Set
Enrichment Analysis (GSEA) to compare the set of genes whose
expression was significantly changed by lithium to those we found
altered by Cpd-60 or SAHA treatment by microarray analysis
($1.2-fold change versus vehicle, Tukey’s HSD post hoc p,0.05).
As McQuillin and colleagues’ study utilized whole brain, we
approximated ‘whole brain’ by compiling our microarray expres-
sion data from PFC, NAc, and HIP. A subset of 11 of the 390
transcripts altered by Cpd-60 across the three regions were among
the 121 modulated by lithium treatment, a statistically significant
overlap (FDR-corrected p,0.001), and included the three most
upregulated transcripts, Agxt2l1, Sgk1, and Tsc22d3 (Table S3). The
direction of regulation was the same between Cpd-60 and lithium
for 9 of the 11 transcripts. Further, there was no significant overlap
between the 288 SAHA-regulated transcripts and those altered by
lithium (p = 0.36). We recognize the limitations in comparing these
datasets and the small extent of the observed overlap. Nonetheless,
these data raise the intriguing possibility that common transcrip-
tional regulatory mechanisms between Cpd-60 and lithium may
underlie their similar effects on mood-related behaviors in mice.
Discussion
Research in post-mortem human brain and preclinical models
has provided evidence that chromatin-mediated neuroplasticity
likely plays an important role in the mechanisms underlying
psychiatric diseases and clinical treatments. A major finding of this
study is that chronic systemic treatment of mice with Cpd-60, a
slow-binding, selective inhibitor of HDAC1 and HDAC2,
modulates brain function as demonstrated by behavioral alter-
ations in paradigms with predictive validity for mood-stabilizing
drugs and antidepressants. These alterations were associated with
significant transcriptional changes in mouse PFC, NAc and HIP,
brain regions involved in regulating mood, that were mediated by
epigenetic modifications as evidenced by increased histone
acetylation at the promoter regions of upregulated transcripts.
Comparatively, the class I and II HDAC inhibitor, SAHA, did not
influence mouse behavior in either paradigm and transcriptional
changes were predominantly localized to the hippocampus despite
evidence of HDAC inhibition in all brain regions examined. These
findings underscore the need to understand the mechanisms by
which HDAC subtypes regulate histone acetylation and gene
transcription, which in turn modulate brain function, as well as
how highly-selective HDAC inhibitors can modulate chromatin-
mediated neuroplasticity and inform treatment design.
Aside from different HDAC selectivity profiles of Cpd-60 and
SAHA, other potential explanations for the distinct behavioral and
molecular effects we observed may be related to brain exposure
and binding kinetics. Systemic Cpd-60 treatment resulted in peak
brain concentrations within 5 min and remained .0.1 mM for at
least 8 hr. In contrast, systemic SAHA treatment, although
reaching peak concentrations quickly, was cleared from the brain
within 2 hr. Nevertheless, SAHA and other HDAC inhibitors are
reported to alter mood-related behaviors when infused directly
into the brain [3,19], suggesting that neuroplasticity and behavior
can be altered if brain levels of HDAC inhibitors are sufficiently
high. The slow binding kinetics of Cpd-60 also support that
sustained inhibition of HDAC enzymes may be potentially
beneficial in neuropsychiatric disease treatment models.
A limitation to interpreting the behavioral and molecular effects
of HDAC inhibitor treatment is that, while the expression of
HDAC subtypes has been examined using harvested brain
[39,40], identifying the neuroanatomical distribution and function
of HDAC subtypes in living animals remains a lasting challenge.
Figure 5. Chromatin immunoprecipitation (ChIP) of nucleus accumbens from Cpd-60 treated mice. (a) Schematic of experimental design
with 10-day administration of Cpd-60 (45 mg/kg, i.p.). (b) Chromatin was immunoprecipitated with an anti-histone H4K12ac-antibody followed by
qPCR targeting regions 1.0 or 0.2 kB upstream or 0.5 kB downstream from the transcription start site (TSS). Transcripts upregulated by Cpd-60
treatment had increased histone acetylation at promoter regions upstream, but not downstream, of the TSS in Cpd-60 treated tissue compared to
vehicle. *p,0.05, **p,0.01, t-test of Cpd-60 versus vehicle.
doi:10.1371/journal.pone.0071323.g005
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Emerging in vivo imaging research investigating radiolabeled
HDAC inhibitor compounds [29] may provide tools to reveal
the distribution of HDAC subtypes and, ideally, enzymatic activity
in the human brain. Meanwhile, this work helps define the
relationship between blood-brain barrier (BBB) penetration of
compounds and their efficacy in the treatment of CNS disorders.
As such, rodent and non-human primate brain imaging data
indicate that systemically delivered MS-275 is limited by poor BBB
permeability [29], despite altering mood-related behaviors in mice
following direct brain infusion [3,19]. Future studies aimed at
identifying HDAC inhibitors with improved selectivity, pharma-
cokinetics, and BBB permeability, as well as those clarifying the
functional distribution of HDAC subtypes in brain, will be critical
to develop HDAC therapies for the CNS.
Insight into the mechanism underlying behavioral changes
induced by chronic Cpd-60 treatment can be gained from
transcriptional changes observed in brain. We interpret the robust
gene expression changes detected in this study as suggesting a role
of promoter region histone acetylation in the selective transcrip-
tional activation of genes that functionally regulate mood-related
neurocircuitry. In our working model, chronic suppression of
HDAC1/2 activity by Cpd-60 treatment alters promoter-region
histone acetylation of a subset of genes, opening chromatin
structure that facilitates transcriptional response to homeostatic
cues and regulatory proteins. Resulting gene expression changes
converge and, based on our behavioral evidence, function to
insulate against challenges to mood-related neurocircuitry.
Based on our microarray data, such homeostatic cues may
include glucocorticoid signaling, a stress-response system altered in
mood disorders [41,42] and previously implicated in chromatin-
mediated neuroplasticity changes underlying mood-related behav-
iors [43]. Lead examples for this model based on the most
significant Cpd-60-induced expression changes include Sgk1 and
Sult1a1, both induced by glucocorticoid signaling [44,45]. Sgk1 and
Sult1a1 were also among the genes reported to be upregulated in
rodent brain following lithium treatment [38], and also by diverse
antidepressant therapies [46]. Further, Sgk1 was increased in rat
brain after administration of the antipsychotic clozapine [47]. In
addition, its protein product SGK phosphorylates and deactivates
glycogen synthase kinase-3 (GSK-3), a known target of lithium
[48], suggesting that protein effectors in the GSK-3/Wnt signaling
pathway (e.g. b-catenin) may mediate transcriptional changes
initiated by treatment with Cpd-60, lithium or other drugs that
alleviate mood dysregulation. Finally, clozapine and lithium
require SGK to suppress nuclear localization of the eukaryotic
transcription factor FOXO [49]. Together, these data support that
the transcriptional effects we observed in Cpd-60-treated mice
may result in part from a glucocorticoid signaling cascade that
incorporates SGK1 and modulates the activity of transcription
factor proteins such as b-catenin and FOXO.
Importantly, we point out that understanding the impact of
selective HDAC inhibitor treatment on behavioral response would
benefit from examination in additional tests and paradigms.
However, we found that treatment with Cpd-60 (45 mg/kg, i.p.)
for longer than 10 days was not well tolerated resulting in
compromised health that precluded more thorough behavioral
characterization. We did not observe any health compromise in
mice treated with SAHA (25 mg/kg, i.p.) for the same time period.
Indeed, this is a major caveat in considering compounds like Cpd-
60 in designing new therapies for mental health disorders where
long-term treatment is often required for efficacy. However, using
these and related HDAC inhibitor tool compounds in basic
research, future studies hold promise to resolve how HDAC
subtype affinity, brain penetrance and clearance relate to both
beneficial and deleterious effects of HDAC inhibition. To this end,
it is interesting to consider the impact of selective HDAC1/2
inhibition on CNS disease models including chronic corticosteroid
exposure [50], as well as chemical and genetic models of
neurodegenerative disease [51–53]. Likewise, emerging com-
pounds such as a highly selective HDAC3 inhibitor recently used
in a study of addiction-related memory [54] will be important in
further describing the role of HDAC enzymes in mood-related
behaviors and how these enzymes may be best targeted in clinical
drug development.
We recognize that, although poorly understood, acetylation of
non-histone proteins likely plays a part in HDAC inhibitor effects
[55]. While Cpd-60 does not functionally inhibit either HDAC5 or
HDAC6, reports have indicated a role for the non-histone targets
of these class II HDACs in regulating emotional behavior, stress
and GC signaling [56–58]. Comparing the behavioral and
molecular responses in these reports to those induced by selective
class I HDAC inhibitors will clarify the role of acetylation of
histone and non-histone proteins to coordinate changes in
chromatin structure and mood-related neurocircuitry. Toward
this aim, the aggregate changes induced by Cpd-60 treatment
represent a signature of gene expression that could be used to
discriminate critical factors induced by clinical drugs or other
chromatin modifying compounds that may influence psychiatric
disease symptoms and treatment. Studies to address this and other
mechanistic questions are ongoing.
In conclusion, efforts in genetic and epigenetic research will
continue to discover and refine the mechanistic underpinnings of
these diseases and lead to targeted, mechanism-based treatments.
Our current findings stand as supportive evidence that selective
inhibition of HDAC1 and HDAC2 results in beneficial changes in
neuroplasticity and may be a novel target for mood disorder
therapy. Overall, the results – and limitations – of this study
underscore the importance of developing brain-penetrant selective
HDAC inhibitors as well as the challenges related of long term,
systemic treatment with HDAC inhibitors. Continued research on
small molecule, selective HDAC inhibitors will advance under-
standing of improvements that can made in engineering chromatin
modifying drugs and how these may be best applied in treating
clinical brain dysfunction.
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